Cascadian Therapeutics, Inc. (NASDAQ:CASC)‘s stock had its “buy” rating restated by Cowen and Company in a report released on Wednesday.

Other research analysts have also recently issued research reports about the company. ValuEngine cut Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Monday, July 17th. Cantor Fitzgerald restated a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a report on Wednesday, May 10th. Finally, BTIG Research started coverage on Cascadian Therapeutics in a report on Friday, April 21st. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $6.17.

Shares of Cascadian Therapeutics (CASC) opened at 3.85 on Wednesday. The firm’s market capitalization is $189.55 million. Cascadian Therapeutics has a 52 week low of $0.84 and a 52 week high of $6.72. The stock has a 50 day moving average of $3.93 and a 200-day moving average of $4.02.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.09. Equities analysts anticipate that Cascadian Therapeutics will post $5.02 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Cascadian Therapeutics, Inc. (CASC) Receives “Buy” Rating from Cowen and Company” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/cascadian-therapeutics-inc-casc-receives-buy-rating-from-cowen-and-company/1467645.html.

Institutional investors have recently modified their holdings of the stock. State of Wisconsin Investment Board acquired a new position in shares of Cascadian Therapeutics during the second quarter valued at about $104,000. BlueCrest Capital Management Ltd acquired a new position in shares of Cascadian Therapeutics during the first quarter valued at about $122,000. Citadel Advisors LLC acquired a new position in shares of Cascadian Therapeutics during the first quarter valued at about $142,000. Bank of America Corp DE raised its position in shares of Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 35,975 shares during the period. Finally, Rhumbline Advisers acquired a new position in shares of Cascadian Therapeutics during the second quarter valued at about $143,000. 82.60% of the stock is currently owned by hedge funds and other institutional investors.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.